December 26, 2019
1 min read
Save

Year in review: New treatment options, updates in ILD, IPF

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Healio Pulmonology has you covered. As 2019 comes to a close, the Editors have compiled a list of updates in interstitial lung disease and idiopathic pulmonary fibrosis that Healio reported on this year.

See below for news on novel treatment options, FDA approvals and more.

FDA approves nintedanib for systemic sclerosis-associated ILD

In September, the FDA approved nintedanib capsules to slow the rate of decline in pulmonary function in adults with ILD associated with systemic sclerosis or scleroderma. Read more

Study lays groundwork for understanding RA-ILD/RA-IPF overlap

Comparative serum protein biomarker profiling may allow researchers to identify patients with rheumatoid arthritis-associated ILD and/or IPF, according to findings published in Arthritis Rheumatology. Read more

Novel therapy for IPF shows sustained long-term benefits

Patients with IPF treated with a recombinant human pentraxin 2 protein exhibited sustained reductions in decline of FVC and 6-minute walking distance at 76 weeks, according to data presented at the American Thoracic Society International Conference and simultaneously published in The Lancet Respiratory Medicine. Read more

INBUILD: Nintedanib slows progression of fibrosing ILD

When compared with placebo, nintedanib slowed the annual rate of decline in FVC in patients with progressive fibrosing ILD other than IPF, researchers reported at the European Respiratory Society International Congress. Read more

Patient-directed YouTube videos on IPF often misleading

Patient-directed IPF videos posted on YouTube are often inaccurate and provide incomplete information, researchers reported. Moreover, many of the videos that support the use of nonrecommended therapies have higher viewing numbers and user engagement data. Read more

Pamrevlumab may be safe, effective in IPF

In a phase 2 trial, pamrevlumab, a fully recombinant human monoclonal antibody against connective tissue growth factor, appeared to reduce the decline in lung function among patients with IPF. Read more

Agreement high between cryobiopsy , surgical biopsy for ILD diagnosis

New data demonstrating good agreement between transbronchial lung cryobiopsy and surgical lung biopsy support the use of the technology as an alternative to surgical biopsy for patients requiring lung tissue for a diagnosis of ILD. Read more

Antifibrotic agents may reduce mortality risk in IPF

Among patients with IPF, the antifibrotic medications pirfenidone and nintedanib were associated with significantly reduced risks for all-cause mortality and hospitalizations vs. those who received no treatment, according to data published in the American Journal of Respiratory and Critical Care Medicine. Read more